• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·002900.SZ
Share

Harbin Medisan Pharmaceutical Co., Ltd. Stocks

CN¥ 12.38Last Updated 12.10.2026

Issuer Rating

4/7
Performance

Average

Risk

Limited

Recommendation

Hold

Market Cap

CN¥ 610.29M

CN¥ 12.38
Key Takeaways

Risk factor

Meaningful price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very poor margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Established in 1996 and based in Harbin, China, Harbin Medisan Pharmaceutical Co., Ltd. specializes in the full lifecycle of chemical pharmaceutical products within China, from research and development to manufacturing and sales. The company's comprehensive product line includes both active pharmaceutical ingredients (APIs) and various finished drug forms. Its offerings address a wide array of medical conditions, encompassing treatments for neurological, cardiovascular, and musculoskeletal systems, systemic infections, nutritional support, fluid balance, and other general healthcare needs.

Company Valuation

Fairly valued
4/7

Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

12.10.2026 16:53

Jennifer Garner's company could see its stock price rise by 50%: Freedom has identified unaccounted-for growth drivers

12.10.2026 16:43

"The bar is being raised for any IPO": What signal does the cancellation of Firmus's listing send to the market?

12.10.2026 15:36

Morning in New York: Oil Caught Between De-escalation and the Risk of New Attacks

12.10.2026 15:03

The Nobel Prize in Economics was awarded to the authors of new approaches to crisis management

12.10.2026 14:48

Slow but sure—a tsunami: IMF chief warns that AI is hitting the labor market and government budgets

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026